Pazopanib: Therapeutic Developments

Overview

Journal Expert Opin Pharmacother

Publisher Informa Healthcare

Specialty Pharmacology

Date 2009 Dec 4

PMID 19954277

Citations 11

Authors

Suwicha Limvorasak

Edwin M Posadas

Affiliations

Soon will be listed here.

Abstract

Pazopanib (Votrient, GW786034) is a potent pan-VEGF inhibitor in advanced clinical development. Like other orally available VEGFR inhibitors, pazopanib is clinically efficacious and well tolerated. The recently reported Phase III clinical trial in metastatic renal cell carcinoma showed activity similar to approved agents with variations in toxicity which has led to its recent FDA approval. Given the growing number of agents in this category, differences not only in single-agent activity but also toxicity and combinatorial potency will probably distinguish pazopanib from other similar agents.

Citing Articles

Exploring the Spectrum of VEGF Inhibitors' Toxicities from Systemic to Intra-Vitreal Usage in Medical Practice.

Santorsola M, Capuozzo M, Nasti G, Sabbatino F, Di Mauro A, Di Mauro G Cancers (Basel). 2024; 16(2).

PMID: 38254839 PMC: 10813960. DOI: 10.3390/cancers16020350.

Vascular normalization: reshaping the tumor microenvironment and augmenting antitumor immunity for ovarian cancer.

Yu P, Wang Y, Yuan D, Sun Y, Qin S, Li T Front Immunol. 2023; 14:1276694.

PMID: 37936692 PMC: 10626545. DOI: 10.3389/fimmu.2023.1276694.

Pazopanib alleviates neuroinflammation and protects dopaminergic neurons in LPS-stimulated mouse model by inhibiting MEK4-JNK-AP-1 pathway.

Sun H, Wu J, Wang R, Zhang S, Xu H, Kaznacheyeva E Acta Pharmacol Sin. 2022; 44(6):1135-1148.

PMID: 36536076 PMC: 10203146. DOI: 10.1038/s41401-022-01030-1.

Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis.

Zhang L, Wang H, Li W, Zhong J, Yu R, Huang X Oncotarget. 2016; 8(2):3289-3303.

PMID: 27924057 PMC: 5356882. DOI: 10.18632/oncotarget.13753.

Pharmacotherapy options in advanced renal cell carcinoma: what role for pazopanib?.

Harrison M Clin Med Insights Oncol. 2011; 5:349-64.

PMID: 22174596 PMC: 3235998. DOI: 10.4137/CMO.S6087.